Clinical Trials Logo

Gout clinical trials

View clinical trials related to Gout.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05522504 Active, not recruiting - Gout Flare Clinical Trials

Distribution of Immune Cells and Their Subtypes in Peripheral Blood of Gout

Start date: September 15, 2022
Phase:
Study type: Observational

The purpose of this study is to evaluate whether immune cells and their subtypes in peripheral blood affects the asymptomatic hyperuricemia, gout flare, intercritical gout and advanced gout.

NCT ID: NCT05328531 Active, not recruiting - Acute Gout Clinical Trials

Clinical Study of Genakumab for Injection in Patients With Acute Gout

Start date: May 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for Injection in patients with acute gout

NCT ID: NCT05309057 Active, not recruiting - Obesity Clinical Trials

Network Meta-analysis of Intermittent Fasting and Cardiometabolic Risk

Start date: November 1, 2020
Phase:
Study type: Observational

Intermittent fasting is a method of restricting calories over a defined period of time and includes regimens such as whole-day fasting, alternate-day fasting, and time-restricted feeding. There is emerging evidence that intermittent fasting or energy restriction might be more beneficial than continuous energy restriction for some risk factors. The effect of intermittent fasting on risk factors associated with obesity, diabetes, and cardiovascular disease, however, is not clear. The European Association for the Study of Diabetes (EASD) has yet to make any recommendations regarding the role of intermittent fasting in the management of diabetes. To inform the update of the EASD Clinical Practice Guidelines for Nutrition Therapy, tthe Diabetes and Nutrition Study Group (DNSG) of the EASD has commissioned a systematic review and network meta-analysis of randomized controlled trials of the effect of different intermittent fasting strategies on established cardiometabolic risk factors. The findings generated by this proposed knowledge synthesis will shape guide current guidelines and improve health outcomes by educating healthcare providers and patients, and by guiding future research design.

NCT ID: NCT05289544 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Phone-Based Based Walk With Ease Program for Adults With Arthritis

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

The objective of this study is to examine the short-term (6-weeks and 6 months) and long-term (1 year) effects of a phone-based version of Walk With Ease intervention.

NCT ID: NCT05253833 Active, not recruiting - Gout Clinical Trials

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

Start date: August 12, 2022
Phase: Phase 2
Study type: Interventional

This study will assess the serum urate lowering effect, tophi reduction, and safety of AR882 alone and in combination with allopurinol in patients with tophaceous gout at two doses compared to allopurinol over 24 weeks.

NCT ID: NCT05006001 Active, not recruiting - Gout Clinical Trials

Evaluation of Colchicine and Nonsteroidal Anti-inflammatory Drug Combination Therapy and Renal Function in Gout Patients

Start date: January 1, 2012
Phase:
Study type: Observational

Our findings are expected to provide real-world evidence of the renal-adverse effects of colchicine and NSAIDs combination therapy in patients with gout, which will guide healthcare professions in optimizing gout treatment regimens and evaluating risks of renal impairment.

NCT ID: NCT04956432 Active, not recruiting - Gout Clinical Trials

A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

Start date: June 15, 2021
Phase: Phase 3
Study type: Interventional

This study will assess the serum uric acid lowering effects and safety of SHR4640 compared to Allopurinol in subjects with gout.

NCT ID: NCT04746989 Active, not recruiting - Gout Clinical Trials

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol

Start date: February 1, 2021
Phase:
Study type: Observational

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

NCT ID: NCT04125459 Active, not recruiting - Gout Clinical Trials

Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout

Start date: January 22, 2020
Phase:
Study type: Observational

Gout is an autoinflammatory disease characterized by flares of painful joint inflammation. This inflammation occurs in response to uric acid that crystallizes. After a gout attack, patients usually enter a period that is accompanied by low grade inflammation but is otherwise relatively asymptomatic. Gout is typically associated with certain markers, and this study is going describe specific markers in patients that are in between gout attacks. Research has been focused on studying this phase between gout attacks in hopes to manage and prevent the onset of future gout attacks. Biopsies will be taken from the affected joint and blood will be drawn from patients who are currently in between gout attacks. This work will provide important information regarding how crystals in the joint lining are associated with chronic inflammation in the periods between gout attacks. Moreover, this study will identify novel biomarkers that may be useful in determining the severity of disease activity through a blood test.

NCT ID: NCT03621215 Active, not recruiting - Gout Flare Clinical Trials

The Effect of Tart Cherry Juice on Risk of Gout Attacks

Start date: July 15, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether consuming tart cherry juice daily for 12 months reduces the risk of gout attacks during this period. Individuals with an existing gout diagnosis and who have experienced at least one gout flare in the past year will be recruited to participate in this study.